Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

(2011) J. Tie et al.   CLINICAL CANCER RESEARCH

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

(2011) James A. McCubrey et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

(2010) A. Fariña-Sarasqueta et al.   ANNALS OF ONCOLOGY

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells

(2010) Caroline Brünner-Kubath et al.   BREAST CANCER RESEARCH AND TREATMENT

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

(2010) E. Halilovic et al.   CANCER RESEARCH

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

(2010) Sergio Rizzo et al.   CANCER TREATMENT REVIEWS

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

(2010) S. A. Aziz et al.   CLINICAL CANCER RESEARCH

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma

(2010) A. Dubrovska et al.   CLINICAL CANCER RESEARCH

Oncogenic mutations in gastric cancer with microsatellite instability

(2010) Giovanni Corso et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

(2010) Gail T. McDonald et al.   EXPERIMENTAL CELL RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

(2010) Jun Sunayama et al.   NEURO-ONCOLOGY

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

(2010) Zacharenia Saridaki   WORLD JOURNAL OF GASTROENTEROLOGY

Status of PI3K inhibition and biomarker development in cancer therapeutics

(2009) B. Markman et al.   ANNALS OF ONCOLOGY

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

The Applicability of mTOR Inhibition in Solid Tumors

(2009) I.R. Konings et al.   CURRENT CANCER DRUG TARGETS

Immunotherapy of cancer

(2009) Hossein Borghaei et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer

(2009) C.-H. Kohne et al.   ONCOLOGIST

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

(2008) Vincent Duronio   BIOCHEMICAL JOURNAL

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

(2008) C. R. Schnell et al.   CANCER RESEARCH

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

(2008) Philipp Baumann et al.   EXPERIMENTAL CELL RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE